Is Ligand Pharmaceuticals (LGND) Still Attractive After Its 165.7% Three Year Share Price Surge

• If you are wondering whether Ligand Pharmaceuticals at around US$195 a share still offers value, the next sections will walk through what the current price might be implying about the business.
• The stock has delivered an 81.6% return over 1 year and 165.7% over 3 years, while the shorter term picture shows a 4.6% decline over 7 days alongside modest gains of 2.1% over 30 days and 2.8% year to date.
• Recent coverage of Ligand Pharmaceuticals has focused on its role in the wider pharmaceuticals and biotech space and how its asset light model and portfolio of partnered programs fit into that context. This background helps frame why the share price has seen strong multi year returns while still moving around meaningfully in the short term.
• On Simply Wall St’s valuation checks, Ligand Pharmaceuticals scores 4 out of 6 on the valuation score. The rest of this article will compare several common valuation approaches and then finish with a broader way to think about what the current price might mean for you.

Ligand Pharmaceuticals delivered 81.6% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Approach 1: Ligand Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business might be worth today by projecting its future cash flows and discounting them back to a present value. It focuses on the cash the company could generate for shareholders over time.

For Ligand Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month Free Cash Flow is about $46.6 million, and analyst and extrapolated estimates point to projected Free Cash Flow of $206.8 million in 2030. Simply Wall St provides a path of annual projections through 2035, combining analyst inputs for nearer years with extrapolated figures further out.

Pulling these projected cash flows together, the DCF output suggests an estimated intrinsic value of roughly $279.18 per share. Compared with a share price around US$195, this implies the stock trades at about a 30.0% discount to that intrinsic value. On this specific cash flow model, Ligand Pharmaceuticals appears to be trading below the estimated intrinsic value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Ligand Pharmaceuticals is undervalued by 30.0%. Track this in your watchlist or portfolio, or discover 61 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Ligand Pharmaceuticals.

Approach 2: Ligand Pharmaceuticals Price vs Earnings

For a profitable company, the P/E ratio is a straightforward way to think about what you are paying for each dollar of earnings, which is why it is often the go to metric. The higher the expected growth and the lower the perceived risk, the more investors are usually willing to pay, which can support a higher P/E. If growth is modest or risks are elevated, a lower, more conservative P/E is often seen as more reasonable.

Ligand Pharmaceuticals currently trades on a P/E of 31.32x. That is very close to the peer average of 31.37x and well above the Pharmaceuticals industry average P/E of 16.66x. Simply Wall St also calculates a proprietary “Fair Ratio” for the P/E, which is 18.42x for Ligand Pharmaceuticals. This Fair Ratio reflects factors such as earnings growth, industry, profit margin, market cap and specific risks, rather than just comparing to broad industry or peer group figures.

Because the Fair Ratio is tailored to the company’s own profile, it can offer a more nuanced anchor for valuation than simple peer or industry comparisons. With the actual P/E of 31.32x sitting above the Fair Ratio of 18.42x, the stock screens as trading at a richer multiple than this framework suggests.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Ligand Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation, and on Simply Wall St this comes through Narratives. With Narratives, you set out your story for Ligand Pharmaceuticals, link that story to explicit forecasts for revenue, earnings and margins, and let the platform on the Community page used by millions of investors convert those inputs into a Fair Value that can be compared against the current share price to help frame buy or sell decisions. Each Narrative automatically updates as new news or earnings arrive. For example, one investor might focus on the higher analyst targets around US$277.0 based on confidence in the royalty portfolio and QTORIN opportunity, while another leans toward the lower US$220.0 end because of concerns about pricing pressure and concentration in a few assets. This gives you a clear sense of how different views on the same company translate into different valuations.

Do you think there’s more to the story for Ligand Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com